Join the Osimertinib group to help and get support from people like you.
Osimertinib News
Molecular Residual Disease Analysis May Predict Disease Recurrence After Lung Cancer Resection
TUESDAY, March 25, 2025 – For patients with resected stage IB-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer, molecular residual disease (MRD) precedes disease-free...
Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
Cambridge, UK. AstraZeneca Press Release--26 September 2024--AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III e...
Tagrisso With the Addition of Chemotherapy Approved in the US for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
19 February 2024 – AstraZeneca’s Tagrisso has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) n...
Tagrisso Approved in the US for the Adjuvant Treatment of Patients with Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer
21 December 2020 – AstraZeneca’s Tagrisso (osimertinib) has been approved in the US for the adjuvant treatment of adult patients with early-stage epidermal growth factor receptor-mutated (EGFRm) non...
FDA Approves Tagrisso (osimertinib) as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer
18 April 2018 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell...
Tagrisso (osimertinib) Receives FDA Full Approval
31 March 2017 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment of patients...
FDA Approves Tagrisso (osimertinib) for EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
Today, the U.S. Food and Drug Administration granted accelerated approval for an oral medication to treat patients with advanced non-small cell lung cancer (NSCLC). Tagrisso (osimertinib) is now...